CRP and renal cell carcinoma: It is thus considered that these inflammatory biomarkers are useful for predicting response and prognosis of patients undergoing immuno‐oncology therapy for RCC, since fluctuations of CRP and NLR values associated with treatment response state were also noted in the present case.